Thank you for your interest in Eleview®. To speak with an Aries sales representative or for general inquiries about Eleview® or Aries, please contact us via the information below.

Learn more about Aries Pharmaceuticals, Inc., including our pipeline.

Aries Pharmaceuticals logo

Get in touch with Aries

Aries Pharmaceuticals, Inc.
The Towers South
9276 Scranton Road
Suite 600
San Diego, CA 92121

Aries Pharmaceuticals, Inc.

For adverse event reports

Please call our toll-free service number to report a device-related adverse event, or for product issues related to Eleview.

1-888-ARIES-08 (888-274-3708)

image of the Eleview® logo

For medical information

Please call our toll-free service number for more medical information.

1-888-ARIES-08 (888-274-3708)

Let us know what you think of Eleview®

Please fill out the evaluation form to share your feedback on your Eleview® experience in practice. We appreciate your time and consideration.

Eleview® submucosal injection agent

You are leaving to visit another Aries Pharmaceuticals, Inc. website.

Cancel Send Request


Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.


Patients with known sensitivity to any of the components contained in Eleview®.


  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.


Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.


The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.